1.  <p>In https://okdermo.com/product-category/eyelash-growth/ , roughly 29% of patients treated with LUMIGAN 0.Three mg/mL single-dose experienced adversarial reactions. Essentially the most incessantly reported hostile reactions were conjuctival hyperaemia (largely hint to mild and of a non-inflammatory nature) occurring in 24% of patients, and eye pruritis occurring in 4% of patients. Roughly 0.7% of patients in the LUMIGAN 0.3 mg/mL single-dose group discontinued as a consequence of any adverse occasion in the 3 month research.</p>
2.  <p>The following antagonistic reactions have been reported during clinical trials with LUMIGAN 0.Three mg/mL single-dose or in the submit-advertising interval. Most were ocular, mild and none was severe:</p>
3.  <p>Quite common (≥1/10); frequent (≥1/100 to &lt;1/10); uncommon (≥1/1,000 to &lt;1/100); rare (≥1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000) and not known (cannot be estimated from available data) adverse reactions are presented according to System Organ Class in Table 1. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p>
4.  <h2>Desk 1</h2>
5.  <p>conjunctival hyperaemia</p>
6.  <p>punctate keratitis, eye irritation, foreign body sensation, dry eye, eye pain, eye pruritus, progress of eyelashes, eyelid erythema</p>
7.  <p>asthenopia, conjunctival oedema, photophobia, lacrimation increased, iris hyperpigmentation, blurred imaginative and prescient, eyelid pruritus, eyelid oedema</p>
8.  <h2>eye discharge, ocular discomfort</h2>
9.  <p>Respiratory, thoracic and mediastinal disorders</p>
10.  <h2>asthma, asthma exacerbation, COPD exacerbation and dyspnoea</h2>
11.  <p>pores and skin hyperpigmentation (periocular)</p>
12.  <h2>hair progress abnormal</h2>
13.  <p>pores and skin discoloration (periocular)</p>
14.  <h2>Immune system disorders</h2>
15.  <span style="display:block;text-align:center;clear:both"></span>
16.  <p>Hypersensitivity reaction together with indicators and symptoms of eye allergy and allergic dermatitis</p>
17.  <p>In clinical studies, over 1800 patients have been handled with LUMIGAN 0.Three mg/mL (multi-dose formulation). On combining the data from section III monotherapy and adjunctive LUMIGAN 0.Three mg/mL (multi-dose formulation) utilization, the most incessantly reported adverse reactions had been:</p>
18.  <p>• growth of eyelashes in up to 45% in the first 12 months with the incidence of latest stories reducing to 7% at 2 years and 2% at three years</p>
19.  <p>• conjunctival hyperaemia (largely hint to mild and thought to be of a non-inflammatory nature) in as much as 44% in the first yr with the incidence of new experiences reducing to 13% at 2 years and 12% at 3 years</p>
20.  <p>• ocular pruritus in as much as 14% of patients in the first yr with the incidence of latest reviews reducing to 3% at 2 years and 0% at 3 years.</p>
21.  <p>Lower than 9% of patients discontinued resulting from any adverse event in the primary 12 months with the incidence of extra affected person discontinuations being 3% at each 2 and 3 years.</p>
22.  <p>Table 2 lists hostile reactions that have been seen in a 12 month clinical examine with LUMIGAN 0.3 mg/mL (multi-dose formulation), however have been reported at the next frequency than with LUMIGAN 0.Three mg/mL (single-dose). Most had been ocular, mild to reasonable, and none have been serious.</p>
23.  <h2>Desk 2</h2>
24.  <p>headache</p>
25.  <h2>quite common</h2>
26.  <p>ocular pruritus, growth of eyelashes</p>
27.  <h2>asthenopia, conjunctival oedema, photophobia, tearing, elevated iris pigmentation; blurred vision</h2>
28.  <p>eyelid pruritus</p>
29.  <p>In addition to the hostile reactions seen with LUMIGAN 0.3 mg/mL single-dose, Desk 3 lists additional adverse reactions that have been seen with LUMIGAN 0.Three mg/mL (multi-dose formulation). Most had been ocular, mild to reasonable, and none had been critical.</p>
30.  <h2>Desk 3</h2>
31.  <p>System Organ class</p>
32.  <h2>Frequency</h2>
33.  <p>Adverse Response</p>
34.  <h2>Nervous system disorders</h2>
35.  <p>dizziness</p>
36.  <h2>Eye disorders</h2>
37.  <p>corneal erosion, ocular burning, allergic conjunctivitis, blepharitis, worsening of visible acuity, eye discharge, visible disturbance, eyelash darkening</p>
38.  <h2>retinal haemorrhage, uveitis, cystoid macular oedema, iritis, blepharospasm, eyelid retraction</h2>
39.  <p>periorbital and lid modifications together with deepening of the eyelid sulcus</p>
40.  
41.  <h2>Vascular disorders</h2>
42.  <p>hypertension</p>
43.  <h2>Gastrointestinal disorders</h2>
44.  <p>nausea</p>
45.  <h2>Skin and subcutaneous tissue disorders</h2>
46.  <p>not identified</p>
47.  <h2>periobital erythema</h2>
48.  <p>General disorders and administration site circumstances</p>
49.  <h2>uncommon</h2>
50.  <p>asthenia</p>
51.  <h2>Investigations</h2>
52.  <p>widespread</p>
53.  <h2>liver perform test abnormal</h2>
54.  <p>Hostile reactions reported in phosphate containing eye drops:</p>
55.  <p>Circumstances of corneal calcification have been reported very rarely in affiliation with the use of phosphate containing eye drops in some patients with considerably broken corneas.</p>
56.  <h2>Reporting of suspected hostile reactions</h2>
57.  <p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the profit/danger steadiness of the medicinal product.</p>
58.